14038
中文   |   English 手机浏览
当前位置： 首页   >  成果及论文
成果及论文

  1.  Luogen Lai, Wanqing Zou, Yan Zhang, Yuanbiao Tu, Simeng Li, Tongxuan Xin, Tianyue Zhou, Shan Xu, Pengwu Zheng*, Qingshan Pan*, Wufu Zhu*, Multifunctional MIL-101 Nanoparticles with Fenton-like Reactions to Co-deliver LL-37 Peptide and Vancomycin for Targeted NIR Imaging and Drug-resistant Bacteria Treatment[J]. Chemical Engineering Journal, 2022,435,135084 

  2. Yan Zhang, Luogen Lai, Yijun Liu, Beini Chen, Jing Yao, Pengwu Zheng*, Qingshan Pan*, Wufu Zhu*, Biomineralized Cascade Enzyme-Encapsulated ZIF-8 Nanoparticles Combined with Antisense Oligonucleotides for Drug-Resistant Bacteria Treatment. ACS Appl. Mater. Interfaces, 2022, 14, 5, 6453–6464

  3.  Zhou Z, He J, Yang F, et al.Design, synthesis and evaluation of anti-proliferative activity of 2-ary- l-4-aminoquinazoline derivatives as EGFR inhibitors[J].Bioorganic Chemistry,2021, 112.

  4.   Hu X, Tang S, Yang F, et al.Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety[J].Molecules,2021, 26 (10).

  5. Zhang J, Xiong H, Yang F, et al.Design, synthesis and biological evaluation of novel 4-(pyrrolo 2,3-d pyrimidine-4-yloxy)benzamide derivatives as potential antitumor agents[J]. Bioorganic & Medicinal Chemistry Letters,2021, 33.

  6.  He J, Zhou Z, Sun X, et al.The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation[J].European Journal of Medicinal Chemistry,2021, 210.

  7. Sun X, Xu S, Yang Z, et al.Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)[J]. Expert Opinion on Therapeutic Patents, 2021, 31 (3): 223-238.

  8.  Xiao Z, Chu C, Zhou L, et al.Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors[J].Bioorganic & Medicinal Chemistry,2020, 28 (19).
  9.  Xiao Z, Zhou Z, Chu C, et al.Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations[J].European Journal of Medicinal Chemistry,2020, 203.

  10. Zhang Q, Liu X, Gan W, et al.Discovery of Triazolo-pyrridazine/-pyrimidine Derivatives Bearing Aromatic (Heterocycle)-Coupled Azole Units as Class II c-Met Inhibitors[J].Acs Omega,2020, 5 (27): 16482-16490.

  11. Zhang Q, Zheng P, Zhu W.Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present)[J].Molecules,2020, 25 (11).

  12. Zhang B, Liu X, Xiong H, et al.Discovery of 1,2,4 triazolo 4,3-a pyrazine derivatives bearing a 4-oxo-pyridazinone moiety as potential c-Met kinase inhibitors[J].New Journal of Chemistry,2020, 44 (21): 9053-9063.

  13.  Xiong H, Zhang J, Zhang Q, et al.Design, synthesis and biological evaluation of 4-(pyridin-4-yloxy)benzamide derivatives bearing a 5-methylpyridazin-3(2H)-one fragment[J].Bioorganic & Medicinal Chemistry Letters,2020, 30 (9).
  14.  Zou W, Ma X, Zheng P.Preparation and functional study of cellulose/carbon quantum dot composites[J].Cellulose,2020, 27 (4): 2099-2113.
  15.  Liu H, Duan Y, Xiong H, et al.Discovery of novel pyrrolo 2,3-b pyridine derivatives bearing 4-oxoquinoline moiety as potential antitumor inhibitor[J].Bioorganic & Medicinal Chemistry Letters,2020, 30 (2).
  16.  Xiong H, Cheng J, Zhang J, et al.Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors[J].Molecules,2020, 25 (1).
  17. Zhang B, Zhang Q, Xiao Z, et al.Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3K alpha/mTOR inhibitors[J].Bioorganic Chemistry,2020, 95.
  18. Zhao B, Zhao C, Hu X, et al.Design, synthesis and 3D-QSAR analysis of novel thiopyranopyrimidine derivatives as potential antitumor agents inhibiting A549 and Hela cancer cells[J].European Journal of Medicinal Chemistry,2020, 185.
  19.  Yu L, Wang Q, Wang C, et al.Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3K alpha Inhibitors[J].Molecules,2019, 24 (19).
  20.  Zhao B, Xiao Z, Qi J, et al.Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFR(L858R/T790M) inhibitors[J].European Journal of Medicinal Chemistry,2019, 163: 367-380.
  21.  Ouyang Y, Zhao B, Chen X, et al.Design, Synthesis and Antitumor Activity of Quinazoline Derivatives Bearing 2,3-Dihydro-indole or 1,2,3,4-Tetrahydroquinoline[J].Letters in Drug Design & Discovery,2019, 16 (5): 533-546.
  22. Wang C, Xu S, Peng L, et al.Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers[J].Journal of Enzyme Inhibition and Medicinal Chemistry,2019, 34 (1): 204-218.